VIDEO: Expansion of intraventricular thrombolysis hinges on trial results

The midpoint results of the CLEAR III trial didn’t set off any safety alarms, as researchers continue to recruit patients, aiming to evaluate the safety and benefit of intraventricular recombinant tissue plasminogen activator.

"The mortality, bleeding, and infection rates are lower than expected, indicating that the study protocol is safe for patients with severe intraventricular hemorrhage," said Dr. Wendy Ziai, chair of the trial’s Safety Event Committee and the principal investigator of the trial at Johns Hopkins University, Baltimore, which is one of 70 sites involved in the trial.

In this video, watch Dr. Ziai speak more about the trial at the International Stroke Conference.

[email protected]

On Twitter @naseemsmiller

The midpoint results of the CLEAR III trial didn’t set off any safety alarms, as researchers continue to recruit patients, aiming to evaluate the safety and benefit of intraventricular recombinant tissue plasminogen activator.

"The mortality, bleeding, and infection rates are lower than expected, indicating that the study protocol is safe for patients with severe intraventricular hemorrhage," said Dr. Wendy Ziai, chair of the trial’s Safety Event Committee and the principal investigator of the trial at Johns Hopkins University, Baltimore, which is one of 70 sites involved in the trial.

In this video, watch Dr. Ziai speak more about the trial at the International Stroke Conference.

[email protected]

On Twitter @naseemsmiller

The midpoint results of the CLEAR III trial didn’t set off any safety alarms, as researchers continue to recruit patients, aiming to evaluate the safety and benefit of intraventricular recombinant tissue plasminogen activator.

"The mortality, bleeding, and infection rates are lower than expected, indicating that the study protocol is safe for patients with severe intraventricular hemorrhage," said Dr. Wendy Ziai, chair of the trial’s Safety Event Committee and the principal investigator of the trial at Johns Hopkins University, Baltimore, which is one of 70 sites involved in the trial.

In this video, watch Dr. Ziai speak more about the trial at the International Stroke Conference.

[email protected]

On Twitter @naseemsmiller